Biora Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Biora Therapeutics (NASDAQ:BIOR) reported Q4 earnings with an EPS of $-0.63, missing estimates by -7%, and a revenue decrease of $14 thousand from the previous year. This follows a pattern from the last quarter where despite beating EPS estimates, the share price dropped by 2% the next day.
March 26, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biora Therapeutics reported a Q4 EPS of $-0.63, missing estimates by -7%, with a revenue decrease of $14 thousand from the previous year. This follows a previous pattern of share price drop post-earnings announcement.
The negative earnings report, missing estimates by -7%, and the historical context of a share price drop following the last quarter's earnings beat, suggest a likely short-term negative impact on BIOR's stock price. The consistent pattern of performance and market reaction strengthens the confidence in this analysis.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100